T. Rowe Price Associates, Inc. 13D and 13G filings for Cerevel Therapeutics Holdings, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2020-12-10 1:14 pm Purchase | 2020-11-30 | 13G | Cerevel Therapeutics Holdings, Inc. CERE | T. Rowe Price Associates, Inc. | 3,639,190 2.800% | 2,124 (+0.06%) | Filing |
| 2020-11-10 3:09 pm Purchase | 2020-10-31 | 13G | Cerevel Therapeutics Holdings, Inc. CERE | T. Rowe Price Associates, Inc. | 3,637,066 18.700% | 3,637,066 (New Position) | Filing |